Oral Androgens in Man-7: Pharmacokinetics of a Novel Oral Testosterone Undecanoate Formulation With Concomitant Inhibition of 5alpha-Reductase by Finasteride.

Trial Profile

Oral Androgens in Man-7: Pharmacokinetics of a Novel Oral Testosterone Undecanoate Formulation With Concomitant Inhibition of 5alpha-Reductase by Finasteride.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2010

At a glance

  • Drugs Finasteride (Primary) ; Testosterone undecanoate (Primary) ; Acyline
  • Indications Alopecia; Benign prostatic hyperplasia; Prostate cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Apr 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 23 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top